Every 8-K that NRC Health (NRC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRC filings page.
NRC Health reported a leadership change in its finance organization. On August 7, 2026, Chief Financial Officer and principal financial officer Shane Harrison tendered his resignation from the company to pursue an outside professional opportunity. His resignation will be effective August 28, 2026. NRC Health stated that it has begun a formal search process for a new Chief Financial Officer to fill the role following his departure.
NRC Health reported second quarter 2026 results, with revenue of $35.4 million, up from $34.0 million a year earlier. Second quarter Total Recurring Contract Value (TRCV) increased 11% year-over-year to $151.9 million, which management views as a leading indicator of future revenue trends.
Despite revenue growth, the company recorded a net loss of $3.3 million, or $(0.15) per diluted share, compared with a $0.1 million loss in the prior-year quarter, as selling, general, and administrative expenses rose to $22.9 million from $17.7 million and non-cash stock compensation and management transition costs increased. For the first six months of 2026, net income was a small loss of $0.1 million versus profit of $5.7 million a year earlier, while adjusted net income was $11.4 million and adjusted EBITDA was $18.8 million, compared with $12.3 million and $20.6 million, respectively, in 2025. Free cash flow for the first half improved to $5.4 million from $(0.5) million, and the board declared a quarterly cash dividend of $0.16 per share payable October 9, 2026.
NRC Health reported results of its 2026 annual stockholder meeting and subsequent governance changes. Stockholders approved amendments to the company’s certificate of incorporation, and an Amended and Restated Certificate of Incorporation became effective on June 24, 2026.
The board also amended the bylaws on June 23, 2026 to align written-consent voting requirements with the new charter, effective upon the charter’s effectiveness. Directors received strong support, with individual nominees generally receiving about 19.8 million votes in favor versus materially smaller totals against, alongside broker non-votes.
NRC Health amended previously granted stock awards for its CEO and two executive vice presidents and approved related cash bonuses to restore the originally intended fully vested ownership and tax treatment. The Committee removed the company’s right to repurchase shares for $1.00 upon certain terminations within three years and granted cash bonuses of approximately $1.9 million to Trent Green and $0.5 million each to Helen Hrdy and Andrew Monich to cover estimated tax obligations tied to the amended awards and bonuses. These changes are expected to create approximately $9.4 million of expense in the second quarter of 2026, including about $6.5 million of non-cash accelerated equity compensation expense and about $2.9 million of cash bonus expense, and to affect the company’s effective tax rate for 2026 while eliminating these awards’ impact on future periods.
NRC Health reported first-quarter 2026 results with revenue of $34.8 million, up from $33.6 million a year earlier, marking its first year-over-year revenue growth since 2023. Net income declined to $3.2 million from $5.8 million, and diluted earnings per share fell to $0.14 from $0.25.
Total Recurring Contract Value rose 13% year-over-year to $152.1 million, and cash flow from operations increased 8% to $7.2 million, driving free cash flow of $5.3 million. The company highlighted signing the largest deal in its 45-year history and declared a quarterly dividend of $0.16 per share, payable July 10, 2026, to shareholders of record on June 26, 2026.
NRC Health filed an 8-K describing several governance and corporate changes approved on April 15, 2026. The company formally changed its legal name from National Research Corporation to NRC Health via a certificate of amendment filed in Delaware, while keeping its NASDAQ ticker symbol “NRC.”
The Board adopted amended and restated bylaws that declassify the Board of Directors, so all seven directors will stand for election annually starting at the June 23, 2026 Annual Meeting, with incumbent directors submitting resignations effective immediately prior to that vote. The bylaws also cap the Board at 12 directors, formally recognize the Chair role, and update shareholder meeting and nomination procedures. Additionally, the Compensation and Talent Committee amended Shane Harrison’s September 29, 2025 equity award of 172,000 restricted shares to allow voting and dividends on unvested shares.
National Research Corporation, doing business as NRC Health, reported that its Total Recurring Contract Value (TRCV) has surpassed $152 million as of March 4, 2026, an all‑time high for the company.
The company said TRCV, which reflects projected revenue over the next 12 months from renewable contracts, increased 6% since the end of 2025 and 13% year‑over‑year. Management framed this growth as evidence of strong, long‑term relationships with health system partners, but emphasized that this update does not represent complete financial results for the quarter ended March 31, 2026.
National Research Corporation filed a current report to furnish a press release announcing its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.
The company states that the information under the results and exhibits sections is being furnished, not filed, under securities laws. It also notes that the materials may include forward-looking statements, which are subject to risks and uncertainties described in its press releases and SEC filings.
National Research Corporation appointed Shane Harrison as Executive Vice President and Chief Financial Officer effective on or about September 25, 2025. On that date Harrison will become the company's principal financial officer and Michael D. Hays will cease serving in that role. The Talent and Compensation Committee approved an annualized base salary of $400,000, a $100,000 cash signing bonus (subject to pro-rated return if Harrison departs before the first anniversary except for certain terminations), and a grant of 172,000 restricted shares that vest 25% after 90 days and 25% on each of the first three anniversaries thereafter. The equity award includes double-trigger vesting on a change in control plus a holding requirement to retain shares until their value equals at least two times his annual base salary. If terminated without cause or resigning for good reason, Harrison is entitled to one year of continued base salary. The filing states no related-party arrangements and includes a press release exhibit announcing the appointment.